Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/NMWtHB94Pi https://t.co/ok43pnagFg

• https://buff.ly/3yS7cIw

Metformin Lowers Gout Risk in Pre-Diabetes A large, propensity score-matched cohort study shows that metformin use in patients with pre-diabetes significantly lowers the risk of future gout. https://t.co/IQ1Z7rhhp1 https://t.co/vYKBKsWh0y

• Metformin Lowers Gout Risk in Pre-Diabetes | RheumNow

CBD Products Disappointing for Pain There is no evidence that CBD products reduce chronic pain, and taking them is a waste of money and potentially harmful to health, according to new research led by the University of Bath in the UK. https://t.co/0NOGOTkpke

• CBD Products Disappointing for Pain | RheumNow

Lupus Research Alliance Grants for Lupus Innovation The LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA). https://t.co/nAlpFyiyUO https://t.co/Rj2JzmmhHO https://t.co/8IG9EkyMad

• Lupus Research Alliance Grants for Lupus Innovation | RheumNow
• https://buff.ly/3wLYNpG

Gangsin: 갱신 Korean: refresh, renew, updated Over the last 20+ years, I have listened to patients confide their personal stories. Some remained paralyzed in their current state of distress, --I was one of them https://t.co/92tu3de4Ja https://t.co/ePGshN9t51 https://t.co/shdaov1ZPf

• Gangsin: 갱신 Korean: refresh, renew, updated | RheumNow
• https://buff.ly/4bIQQki

JAMA full read comprehensive review of 'Chronic Pruritus' affecting 22%, 1% of all out pt visits - Dx algorithm - Pathophys - Rx options - Alternative Rx https://t.co/epiP8Yi1Oz https://t.co/GsORbADJZy https://t.co/K7Q6Yrx1yI

• Review: Chronic Pruritus
• https://buff.ly/3Xb6OyS

Hypertension not associated with High NSAID Doses in AxSpA At the SPARTAN meeting, Dr.Meade-Aguilar reported that amongst axSpA patients receiving NSAIDs, there was no diff in the risk for hypertension when comparing those on high vs. low dose NSAIDs. https://t.co/4XLr01wwo1 https://t.co/hdBYec6wmd

• Hypertension not associated with High NSAID Doses in AxSpA | RheumNow

2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/qJykCPMn4U https://t.co/zVOTxLkW9R https://t.co/3I4eOfPYWk

• Efficacy and safety of bimekizumab in patients with moderate-to-severe hidraden…
• https://buff.ly/3R7FZIn

No Great Options for Treating VEXAS For patients w/ VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed. https://t.co/xCQYHwgUH9 https://t.co/N5Q03izr8u https://t.co/csIixQO3sJ

• No Great Options for Treating VEXAS | RheumNow
• https://buff.ly/3VmrPW2

Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis A single center study demonstrates that biologic treatment of PsO significantly reduces the likelihood of PsA development; suggesting a role for more aggressive treatment of PsO. https://t.co/VHk2KEsP8d https://t.co/1r4zVAzrMw

• Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis | RheumN…

ACR Website to Support PCPs The American College of Rheumatology recently launched Rheumatology for Primary Care, a new resource for PCP and APP offering them expanded support and guidance to identify rheumatic diseases in their patients. https://t.co/yZbpG3598O https://t.co/S4oYNMrdqt

• ACR Website to Support Primary Care Practitioners | RheumNow

Colchicine prophylaxis w/ allopurinol (“start-low go-slow” 100mg escalation strategy), is best used in pts w/ gout flare in month prior to allopurinol. Longer prophylaxis may be required w/ ongoing flares in 1st 6mos of allopurinol if T2T not achieved https://t.co/qWUwrAcCJZ https://t.co/6S7Y6p7BnF

• Predicting gout flares in people starting allopurinol using the start‐low go‐sl…

Ramosetron,a 5-HT3 recept antagonist used for post-op N/V,t has been used for adjunctive pain Rx & IBS. An 80 FM pt DBRCT tested PBO vs Ramosetron (.3 mg/day IV x5d). @d5 had signif better VAS pain (1.18  vs 0.54, p< 0.05), but didnt persist till day 28 https://t.co/0ABduv8Nlq https://t.co/WGlxIhst1o

• Ramosetron as an add-on therapy for refractory fibromyalgia: A randomized, doub…

Anakinra in COVID showed mixed (often negative) results. But this Turkish retrospective observational study comparing standard of care to IV anakinra in severe COVID pts. IV ANAK had less thromboembolic event (5% vs 12.3%, p = 0.038), better survival https://t.co/4webWJKEfB https://t.co/85GnCd6N8O

• Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndr…

Forbes on the future of CAR-T cell therapy - A Gamechanger For Autoimmune Diseases. Innovation, costs, more trials and regulatory differences for autoimmune (vs cancer) patietns? https://t.co/1Yg40HPTzh https://t.co/NqCwEzmZ1g

• https://buff.ly/4aJ54jy